PFE

Pfizer, Inc.

53.91
USD
-0.15%
53.91
USD
-0.15%
38.48 61.71
52 weeks
52 weeks

Mkt Cap 300.72B

Shares Out 5.58B

Chat
Send me real-time posts from this site at my email

dosed the first patient in a phase 2 trial evaluating an Omicron variant-specific COVID-19 vaccine

The trial will include two cohorts: One who received two doses of Moderna original COVID vaccine, and the other who received two doses plus a booster shot. Separately, the company also announced data on the effects of a booster on Omicron neutralization. Results showed that neutralization declined 6.3-fold six months from peak titers at 29 days after a booster, but antibodies against the variant were still detectable.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue